OncoMatch/Clinical Trials/NCT04099966

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Is NCT04099966 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies alpha beta depletion for acute leukemia.

Phase 2RecruitingMitchell CairoNCT04099966Data as of May 2026

Treatment: alpha beta depletion — Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Non-Hodgkin Lymphoma

Hodgkin Lymphoma

Biomarker criteria

Allowed: FLT3 mutation/duplication

FLT3 mutation/duplication

Prior therapy

Cannot have received: allogeneic hematopoietic stem cell transplant

Exception: unless being done as a boost

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

New York Medical College · Valhalla, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify